{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advate+%28Low+Dose%29",
    "query": {
      "intervention": "Advate (Low Dose)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advate+%28Low+Dose%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-16T01:28:39.592Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04030052",
      "title": "Emicizumab PUPs and Nuwiq ITI Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Nuwiq (low dose protocol)",
          "type": "DRUG"
        },
        {
          "name": "HEMLIBRA",
          "type": "DRUG"
        },
        {
          "name": "Nuwiq (Atlanta protocol)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-02-17",
      "completion_date": "2023-01-19",
      "has_results": false,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-09-16T01:28:39.592Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04030052"
    },
    {
      "nct_id": "NCT00212472",
      "title": "International Immune Tolerance Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hemophilia A With Inhibitors"
      ],
      "interventions": [
        {
          "name": "Factor VIII concentrates",
          "type": "DRUG"
        },
        {
          "name": "Low-dose treatment",
          "type": "OTHER"
        },
        {
          "name": "High-dose treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "New York Presbyterian Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "7 Years",
        "sex": "ALL",
        "summary": "Up to 7 Years"
      },
      "enrollment_count": 134,
      "start_date": "2002-07",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2009-12-07",
      "last_synced_at": "2026-09-16T01:28:39.592Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Duarte, California • Orange, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00212472"
    },
    {
      "nct_id": "NCT02234323",
      "title": "An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rFVIIIFc",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bioverativ, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "5 Years",
        "sex": "MALE",
        "summary": "Up to 5 Years · Male only"
      },
      "enrollment_count": 108,
      "start_date": "2015-01-12",
      "completion_date": "2019-09-23",
      "has_results": true,
      "last_update_posted_date": "2022-04-11",
      "last_synced_at": "2026-09-16T01:28:39.592Z",
      "location_count": 20,
      "location_summary": "Little Rock, Arkansas • Duarte, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02234323"
    },
    {
      "nct_id": "NCT03272568",
      "title": "Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hemophilia",
        "Menstrual Flow Excessive"
      ],
      "interventions": [
        {
          "name": "Recombinant FVIII Fc fusion product Eloctate",
          "type": "DRUG"
        },
        {
          "name": "Recombinant FIX Fc fusion product Alprolix",
          "type": "DRUG"
        },
        {
          "name": "Patient-operated diagnostic device for anemia AnemoCheck.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 55 Years · Female only"
      },
      "enrollment_count": 3,
      "start_date": "2018-02-14",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-05-18",
      "last_synced_at": "2026-09-16T01:28:39.592Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03272568"
    },
    {
      "nct_id": "NCT01376700",
      "title": "Early Prophylaxis Immunologic Challenge (EPIC) Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "1 Year",
        "sex": "MALE",
        "summary": "Up to 1 Year · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2011-08-26",
      "completion_date": "2012-11-16",
      "has_results": true,
      "last_update_posted_date": "2021-05-24",
      "last_synced_at": "2026-09-16T01:28:39.592Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • New Brunswick, New Jersey",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01376700"
    },
    {
      "nct_id": "NCT01233258",
      "title": "A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rFVIII (BAY81-8973) on demand",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rFVIII (BAY81-8973) prophylaxis low-dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rFVIII (BAY81-8973) prophylaxis high-dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 80,
      "start_date": "2011-01",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2016-11-28",
      "last_synced_at": "2026-09-16T01:28:39.592Z",
      "location_count": 2,
      "location_summary": "Dayton, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Dayton",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01233258"
    },
    {
      "nct_id": "NCT02615691",
      "title": "A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "PEGylated Recombinant Factor VIII",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ITI",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "Up to 5 Years"
      },
      "enrollment_count": 120,
      "start_date": "2015-11-12",
      "completion_date": "2024-10-29",
      "has_results": true,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-09-16T01:28:39.592Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cupertino",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02615691"
    },
    {
      "nct_id": "NCT00629837",
      "title": "Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Factor VIII (Kogenate FS, BAY14-2222)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "12 Years to 60 Years · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2005-09",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2014-11-18",
      "last_synced_at": "2026-09-16T01:28:39.592Z",
      "location_count": 2,
      "location_summary": "Davis, California • Orange, California",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00629837"
    },
    {
      "nct_id": "NCT01027377",
      "title": "Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Hemophilia A"
      ],
      "interventions": [
        {
          "name": "rFVIIIFc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bioverativ Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2009-12",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-16T01:28:39.592Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Sacramento, California • Waltham, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Waltham",
          "state": "Massachusetts"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01027377"
    },
    {
      "nct_id": "NCT03205163",
      "title": "A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Advate (Low Dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Advate (High Dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BIVV001 (Low Dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BIVV001 (High Dose)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bioverativ, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2017-08-28",
      "completion_date": "2018-11-12",
      "has_results": true,
      "last_update_posted_date": "2022-04-19",
      "last_synced_at": "2026-09-16T01:28:39.592Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "East Lansing",
          "state": "Michigan"
        },
        {
          "city": "Madison",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03205163"
    }
  ]
}